Bangladesh

Support for Vaccine: Measles Rubella
This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Bangladesh
2. Vaccine grant number: 19-BGD-34a-X, 19-BGD-35a-Y
3. Date of Decision Letter: 26 June 2019
4. Date of the Partnership Framework Agreement: 24 June 2013
5. Programme title: New Vaccine Support (NVS), Measles Rubella, Follow-up campaign
6. Vaccine type: Measles Rubella
7. Requested product presentation and formulation of vaccine:
   Measles Rubella, 10 dose(s) per vial, LYOPHILIZED
8. Programme Duration:* 2019
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)

| Programme Budget (US$) | n/a | 2019 | 2020 | 2021 | 2022 | 2023 | Total*
|------------------------|-----|------|------|------|------|------|-------
| n/a                   |     | 10,749,000 |     |      |      |      | 10,749,000 |

10. Vaccine introduction grant
    Not applicable

11. Product switch grant
    Not applicable

12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement)

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds</th>
<th>n/a</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vaccine doses</td>
<td></td>
<td>16,509,900</td>
<td></td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>n/a</td>
<td>10,749,000</td>
<td></td>
</tr>
</tbody>
</table>

13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

14. Self-procurement: Not applicable

---

* This is the entire duration of the programme.
* This is the total amount endorsed by Gavi for the entire duration of the programme.
* This is the amount that Gavi has approved.
15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group: Preparatory transition phase

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year:

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Country funds in each year</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vaccine doses</td>
<td>869,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Number of AD syringes</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Number of re-constitution syringes</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Value of vaccine doses (US$)</td>
<td>556,122</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total co-financing payments (US$) (including freight)</td>
<td>566,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

16. Operational support for campaigns:

<table>
<thead>
<tr>
<th>Year</th>
<th>Grant Number</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>19-BGD-35a-Y</td>
<td>8,611,116</td>
</tr>
</tbody>
</table>

17. Additional Reporting Requirements:

| Due dates | 31 March 2020 | 15 May 2020 | N/A |

To prepare for the annual procurement of vaccines, Country shall submit the following information each year:

- vaccine stock levels including buffer stock, by end of March;
- number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.
- Countries shall report the actual switch date in the first renewal request following the actual implementation.

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.

To report on national and sub-national programmatic readiness using the WHO Readiness Assessment Tool (or equivalent) at the recommended time points.

Starting 15 months prior to campaign date, up to 1 week before the campaign, at the recommended time points of the tool.
18. Financial clarifications: Country shall provide the following clarifications to Gavi*:

Not applicable

* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.

19. Other conditions:
- Ministry of Health and Family Welfare of Bangladesh to confirm procurement agency/arrangements for related injection safety devices
- Government of Bangladesh to share letter of commitment that expansion of the campaign age range will not jeopardise the target of 95% coverage for the Gavi-supported 9-59 month group; that the full cost of the additional vaccines and operational costs will be covered by Government (or other donor) resources; and that Gavi operational cost funds will not be used for the higher age range.
- As available a copy of the revised Plan of Action and revised MNC&AH Operational Plan showing the allocation of resources to the campaign.

As a condition to Gavi’s support for measles and rubella, country will be required to fully self-finance with domestic resources the measles component of the first dose of measles containing vaccine (MCV1) in its national immunisation programme for 2018 and onwards.

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minimum number of doses to be financed from domestic resources</td>
<td>2,599,441</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Minimum amount to be financed from domestic resources (US$)</td>
<td>1,663,642</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
26 June 2019